Content |
Radiopharmaceuticals are diagnostic or therapeutic agents containing radioactive nuclides. They are used for biomedical research, radioisotope diagnosis and treatment of various diseases, mainly for radiation therapy of malignant tumors.
2024: Johnson & Johnson prostate cancer radiopharmaceutical causes four deaths
At the end of May 2024, Johnson & Johnson released the results of the first phase of clinical trials of the radiopharmaceutical JNJ-6420, designed to treat prostate cancer. The drug has shown promising efficacy, but four patients treated with this therapy have died. Read more here.
2016: Market size of $4.8 billion
In February 2017, the analytical company Future Market Insights published the results of a study of the global radiopharmaceutical market. Its volume, as experts predict, will almost double in 10 years.
Future Market Insights estimates that global sales of radioactive drugs reached $4.8 billion in 2016. By 2026, the market will increase to $8.5 billion, and its average annual growth rate will be measured at 5.9%.
This rise will be ensured by the increasing importance of radioactive compounds for the treatment of cancer and cardiovascular disease. In addition, according to experts, the use of such drugs in oncological drugs is increasing, since research institutes have methods for using radioisotopes to prevent the development of malignant tumors, cells and tissues.
Analysts cite the short half-life of such products and the lack of certain rules and regulations necessary to establish commercial production of such products as barriers to the growth of the radiopharmaceutical market.
According to 2016 Future Market Insights, Siemens Healthineers is the largest manufacturer of radiopharmaceuticals. She will remain the leader in subsequent years and will have a market share exceeding 40%, researchers predict.
In regional consideration, the largest sales of radiopharmaceuticals are in North America. By 2026, the same region will take about 50% of global revenue on the market, and the second place will be taken by Western Europe with a drug turnover of $1.6 billion.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |